- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Asia and Africa Lateral Flow Assay Market is expected to reach US$ 2,159.62 million by 2028
May 23, 2023
Non-Gelatin Empty Capsules Market is expected to reach US$ 4.64 billion by 2030
Feb 14, 2024
DisposeRx Adds New Community Outreach Partners to Stop Prescription Drug Abuse
Jun 10, 2020
US Mail Order Pharmacy Market is expected to reach US$ 1,71,883.03 million by 2030
Oct 16, 2023
Clinical Trials Market is expected to reach US$ 76,023.44 million by 2028
Jul 04, 2023
South & Central America Gastrointestinal Drugs Market: Business Growth, Development Factors, Applications, and Future Prospects
Dec 15, 2020
Alzheimer's Drugs Market is expected to reach US$ 22.01 billion by 2030
Feb 14, 2024
Follow us on
